-EN備份-SNA02
Indication
Cancers
Product Advantages
1.Low cost.
2.Low immunogenicity.
3.Short half-life.
4.Easy to be modified.
2.Low immunogenicity.
3.Short half-life.
4.Easy to be modified.
Status
Pre-clinical stage
Mechanism
It binds to PD-L1 ligand on tumor cells and blocks the ability of tumor cells to inhibit host immune cells.
Potential Market
2The sales of PD-1 / PD-L1 antibody drugs in 2017 amounted to US $10 billion.
- T-cell receptor (TCR) on the surface of human T cells and multiple immune checkpoint proteins have the abilities to regulate the T cell activity. PD-1 ligand could bind to PD-L1 (Programmed death-ligand 1) receptor on tumor cells resulting in loss of anti-tumor ability of T cell and the escape of cancer cells from the immune system. Therefore, blocking the interaction between PD-1 and PD-L1 is a major development direction of tumor immunotherapy.
- SNA02 is a DNA aptamer drug which was development by Academia Sinica and authorized exclusively to Fountain Biopharma. SNA02 can specifically target PD-L1 receptor on tumor cells and blocks the ability of tumor cells to inhibit host immune cells that leads host immune cell activated to eliminate cancer cells. So far, SNA02 treatment is on the pre-clinical stage. We had finished aptamer sequence optimization, drug modification and cell-based pharmacology. Moreover, we had observed similar efficacy in the tumor animal model compared to PD-L1 antibody drug. The results indicate that SNA02 can inhibit the 60% growth of CT26 colon tumor and 50% growth of Lewis lung tumor. We expect that we will enter the clinical development stage in 2020.
- Because nucleic acid drugs have characteristics of easy site-specific modification and conjugation with other drugs, the development of SNA02 aptamer drug will be more competitive in price and subsequent application than antibody drugs in the future. Moreover, aptamer drugs have low immunogenicity and short half-life characteristics that will largely reduce the incidents of immune-related adverse events (irAEs).
- SNA02 will be the first aptamer drug of immune checkpoint proteins in the history if SNA02 develops successfully. Compared with antibody drugs on the market, SNA02 is not only cheaper and also fewer side effects which is enough to shake up the market of immune checkpoint drugs.
